The clinical landscape of managing patients with CKD

10' education - May 21, 2019 - ISN-WCN 2019 - Prof. David Cherney - Toronto, ON, Canada

ISN-WCN 2019 Prof. David Cherney explains the major mechanisms underlying the protective effects of SGLT2 inhibition, followed by effects of SGLT2 inhibitors in non-diabetic kidney disease and future trials.

Video navigation menu

How do SGLT2 inhibitors work? 00:43
Hemodynamic effects of SGLT2 inhibitors in animals and human 01:20
Effects of SGLT2-i in non-diabetic kidney disease 08:24
Future trials 10:26

Educational information

This lecture by prof. David Cherney was part of a CME accredited symposium "SGLT2 inhibition in CKD: Discussing the key questions and evidence"

Faculty

Prof. David Cherney - Associate Professor, Department of Medicine, University of Toronto, ON, Canada

Disclosures

This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme.

Funding

Funding for this educational program was provided by an unrestricted educational grant from Boehringer Ingelheim/Lilly.

View slides of prof. Cherney View our meeting report

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.